Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Krejsgaard, TF, Ralfkiaer, U, Clasen-Linde, E, Eriksen, KWK, Kopp, KLM, Bonefeld, CM, Geisler, C, Dabelsteen, SAM, Wasik, MA, Ralfkiaer, E, Woetmann, A & Odum, N 2011, 'Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway' Journal of Investigative Dermatology, bind 131, nr. 6, s. 1331-8. https://doi.org/10.1038/jid.2011.27

APA

CBE

MLA

Vancouver

Author

Krejsgaard, Thorbjørn Frej ; Ralfkiaer, Ulrik ; Clasen-Linde, Erik ; Eriksen, Karsten Wessel Kam ; Kopp, Katharina Luise Maria ; Bonefeld, Charlotte Menné ; Geisler, Carsten ; Dabelsteen, Sally Anne Malene ; Wasik, Mariusz A ; Ralfkiaer, Elisabeth ; Woetmann, Anders ; Odum, Niels. / Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. I: Journal of Investigative Dermatology. 2011 ; Bind 131, Nr. 6. s. 1331-8.

Bibtex

@article{3c70b5aaf315429e8a0e65f07d8d8e47,
title = "Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway",
abstract = "IL-17 is a proinflammatory cytokine that is crucial for the host's protection against a range of extracellular pathogens. However, inappropriately regulated expression of IL-17 is associated with the development of inflammatory diseases and cancer. In cutaneous T-cell lymphoma (CTCL), malignant T cells gradually accumulate in skin lesions characterized by massive chronic inflammation, suggesting that IL-17 could be involved in the pathogenesis. In this study we show that IL-17 protein is present in 10 of 13 examined skin lesions but not in sera from 28 CTCL patients. Importantly, IL-17 expression is primarily observed in atypical lymphocytes with characteristic neoplastic cell morphology. In accordance, malignant T-cell lines from CTCL patients produce IL-17 and the synthesis is selectively increased by IL-2 receptor β chain cytokines. Small-molecule inhibitors or small interfering RNA against Jak3 and signal transducer and activator of transcription 3 (Stat3) reduce the production of IL-17, showing that the Jak3/Stat3 pathway promotes the expression of the cytokine. In summary, our findings indicate that the malignant T cells in CTCL lesions express IL-17 and that this expression is promoted by the Jak3/Stat3 pathway.",
keywords = "Cell Line, Tumor, Humans, Interleukin-17, Janus Kinase 3, Lymphoma, T-Cell, Cutaneous, STAT3 Transcription Factor, Signal Transduction, Skin Neoplasms, T-Lymphocytes",
author = "Krejsgaard, {Thorbj{\o}rn Frej} and Ulrik Ralfkiaer and Erik Clasen-Linde and Eriksen, {Karsten Wessel Kam} and Kopp, {Katharina Luise Maria} and Bonefeld, {Charlotte Menn{\'e}} and Carsten Geisler and Dabelsteen, {Sally Anne Malene} and Wasik, {Mariusz A} and Elisabeth Ralfkiaer and Anders Woetmann and Niels Odum",
year = "2011",
doi = "10.1038/jid.2011.27",
language = "English",
volume = "131",
pages = "1331--8",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "6",

}

RIS

TY - JOUR

T1 - Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway

AU - Krejsgaard, Thorbjørn Frej

AU - Ralfkiaer, Ulrik

AU - Clasen-Linde, Erik

AU - Eriksen, Karsten Wessel Kam

AU - Kopp, Katharina Luise Maria

AU - Bonefeld, Charlotte Menné

AU - Geisler, Carsten

AU - Dabelsteen, Sally Anne Malene

AU - Wasik, Mariusz A

AU - Ralfkiaer, Elisabeth

AU - Woetmann, Anders

AU - Odum, Niels

PY - 2011

Y1 - 2011

N2 - IL-17 is a proinflammatory cytokine that is crucial for the host's protection against a range of extracellular pathogens. However, inappropriately regulated expression of IL-17 is associated with the development of inflammatory diseases and cancer. In cutaneous T-cell lymphoma (CTCL), malignant T cells gradually accumulate in skin lesions characterized by massive chronic inflammation, suggesting that IL-17 could be involved in the pathogenesis. In this study we show that IL-17 protein is present in 10 of 13 examined skin lesions but not in sera from 28 CTCL patients. Importantly, IL-17 expression is primarily observed in atypical lymphocytes with characteristic neoplastic cell morphology. In accordance, malignant T-cell lines from CTCL patients produce IL-17 and the synthesis is selectively increased by IL-2 receptor β chain cytokines. Small-molecule inhibitors or small interfering RNA against Jak3 and signal transducer and activator of transcription 3 (Stat3) reduce the production of IL-17, showing that the Jak3/Stat3 pathway promotes the expression of the cytokine. In summary, our findings indicate that the malignant T cells in CTCL lesions express IL-17 and that this expression is promoted by the Jak3/Stat3 pathway.

AB - IL-17 is a proinflammatory cytokine that is crucial for the host's protection against a range of extracellular pathogens. However, inappropriately regulated expression of IL-17 is associated with the development of inflammatory diseases and cancer. In cutaneous T-cell lymphoma (CTCL), malignant T cells gradually accumulate in skin lesions characterized by massive chronic inflammation, suggesting that IL-17 could be involved in the pathogenesis. In this study we show that IL-17 protein is present in 10 of 13 examined skin lesions but not in sera from 28 CTCL patients. Importantly, IL-17 expression is primarily observed in atypical lymphocytes with characteristic neoplastic cell morphology. In accordance, malignant T-cell lines from CTCL patients produce IL-17 and the synthesis is selectively increased by IL-2 receptor β chain cytokines. Small-molecule inhibitors or small interfering RNA against Jak3 and signal transducer and activator of transcription 3 (Stat3) reduce the production of IL-17, showing that the Jak3/Stat3 pathway promotes the expression of the cytokine. In summary, our findings indicate that the malignant T cells in CTCL lesions express IL-17 and that this expression is promoted by the Jak3/Stat3 pathway.

KW - Cell Line, Tumor

KW - Humans

KW - Interleukin-17

KW - Janus Kinase 3

KW - Lymphoma, T-Cell, Cutaneous

KW - STAT3 Transcription Factor

KW - Signal Transduction

KW - Skin Neoplasms

KW - T-Lymphocytes

U2 - 10.1038/jid.2011.27

DO - 10.1038/jid.2011.27

M3 - Journal article

VL - 131

SP - 1331

EP - 1338

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 6

ER -

ID: 33230272